TITLE

Angiotensin receptor blockers and cancer: safety review

PUB. DATE
December 2010
SOURCE
WHO Drug Information;2010, Vol. 24 Issue 4, p301
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a 2010 decision which the U.S. Food and Drug Administration made to conduct a review of the class of medications known as angiotensin receptor blockers after a study was published which suggested the medications may be associated with a small increased risk of cancer.
ACCESSION #
60164474

 

Related Articles

  • FDA approves Exforge HCT for treatment of hypertension.  // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p59 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to the antihypertensive drug Exforge HCT for patients with moderate-to-severe hypertension.

  • The year's new drugs. Rodman, Morton J. // RN;Jan80, Vol. 43 Issue 1, p97 

    Provides information on several drugs approved by the United States Food and Drug Administration in 1979. Pain relievers; Prompt relief for menstrual symptoms; Antihypertensive diuretic.

  • Olmesartan label to warn of sprue-like side effects.  // Reactions Weekly;7/13/2013, Issue 1461, p4 

    The article reports that the labels for the antihypertensive olmesartan medoxomil which are to be updated by the U.S. Food and Durgs Administration (FDA) to warn the risk of sprue-like enteropathy.

  • Fixed combination for hypertension.  // Modern Medicine;Sep95, Vol. 63 Issue 9, p27 

    Reports that the US Food and Drug Administration has approved Amlodipine/benazil HCL capsules, the first class of a new class of fixed combination antihypertensive. Availability; Addition of benazepril.

  • Two diabetes trials leave Benicar at a crossroads.  // Reactions Weekly;6/19/2010, Issue 1306, p2 

    The article deals with the safety review of the antihypertensive medication, olmesartan, being conducted by the U.S. Food and Drug Administration in June 2010.

  • Increased risk of prostate cancer. Elliott, William T. // Primary Care Reports;Aug2011 Pharmacology Watch, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has warned about the association between the 5-alfa reductase inhibitors finasteride and dutasteride and increased risk of high-grade prostate cancer. Finasteride and dutasteride are marketed for benign prostate hypertrophy....

  • Medication Safety and Reliability. FDA warns 5-ARIs may increase the risk of high-grade prostate cancer.  // Formulary;Aug2011, Vol. 46 Issue 8, p313 

    The article reports the U.S. Food and Drug Administration released a warning that two 5-alpha-reductase inhibitors (5-ARIs) may increase the risk of high-grade prostate cancer. The 5-ARIs finasteride and dutasteride are used for treating benign prostatic hyperplasia. Two clinical trials,...

  • 5-ARIs to reduce PCa risk: Urologists' views are mixed. Nash, Karen // Urology Times;Mar2011, Vol. 39 Issue 3, p36 

    The article presents opinion of various doctors on the U.S. Food and Drug Administration (FDA) committee's decision against the use of 5-alpha-reductase inhibitors to reduce prostate cancer risk. According to doctor Murali Ankem, results of studies conducted by the committee to know the effect...

  • FDA Rejects Aspartame-Ban Petitions.  // Tufts University Health & Nutrition Letter;Mar2015, Vol. 33 Issue 1, p2 

    The article reports on the decision of the U.S. Food and Drug Administration to change its position that zero-calorie sweetener aspartame is safe for the general population, rejecting two citizen petitions calling for its ban.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics